William Blair Predicts uniQure's Q3 Earnings (NASDAQ:QURE)

Key Points

• William Blair upgraded their Q3 2025 earnings per share estimate for uniQure to ($0.63), reflecting an improvement from the previous estimate of ($0.76), while the company's full-year earnings consensus estimate remains at ($3.75).
• The stock has received a mix of ratings from analysts, with a consensus rating of “Moderate Buy” and a price target average of $36.55, although the stock price recently decreased by 3.7% to $13.92.
• uniQure reported a quarterly loss of ($0.69) EPS, surpassing analyst expectations, and achieved revenue of $5.26 million, which is higher than the consensus estimate of $5.00 million.

uniQure N.V. (NASDAQ:QURE - Free Report) - Investment analysts at William Blair raised their Q3 2025 earnings per share estimates for shares of uniQure in a research note issued on Tuesday, July 29th. William Blair analyst S. Corwin now expects that the biotechnology company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.76). The consensus estimate for uniQure's current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure's Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.74) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($2.35) EPS.

A number of other brokerages have also recently commented on QURE. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research note on Wednesday, July 30th. Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Finally, Chardan Capital set a $35.00 price target on uniQure and gave the company a "buy" rating in a research report on Tuesday, July 29th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, uniQure presently has a consensus rating of "Moderate Buy" and an average price target of $36.55.

uniQure Trading Up 0.3%

NASDAQ QURE traded up $0.04 during trading hours on Friday, hitting $13.81. 844,500 shares of the company's stock were exchanged, compared to its average volume of 1,418,938. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a 1-year low of $4.45 and a 1-year high of $19.18. The stock has a 50-day simple moving average of $14.83 and a 200 day simple moving average of $13.68. The firm has a market cap of $757.97 million, a price-to-earnings ratio of -3.51 and a beta of 0.11.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. The business had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million.

Hedge Funds Weigh In On uniQure

Hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new stake in uniQure in the second quarter worth $117,000. ADAR1 Capital Management LLC bought a new stake in uniQure in the fourth quarter worth $177,000. Mraz Amerine & Associates Inc. bought a new position in shares of uniQure during the first quarter valued at $106,000. Teacher Retirement System of Texas purchased a new stake in shares of uniQure during the second quarter valued at $151,000. Finally, Wells Fargo & Company MN boosted its position in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director David D. Meek sold 2,112 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the transaction, the director directly owned 34,190 shares in the company, valued at $494,045.50. This trade represents a 5.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Madhavan Balachandran sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director directly owned 37,697 shares of the company's stock, valued at $544,721.65. The trade was a 5.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock worth $322,426 in the last 90 days. 4.79% of the stock is currently owned by company insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.